{"id":3361,"date":"2026-09-01T21:27:29","date_gmt":"2026-09-01T20:27:29","guid":{"rendered":"https:\/\/seamlessbio.de\/?p=3361"},"modified":"2026-09-01T21:27:31","modified_gmt":"2026-09-01T20:27:31","slug":"fbs-vs-serum-free-aav-production-when-to-switch","status":"publish","type":"post","link":"https:\/\/seamlessbio.de\/de\/fbs-vs-serum-free-aav-production-when-to-switch\/","title":{"rendered":"FBS vs. Serum-Free for AAV Production"},"content":{"rendered":"<p><!--\nWORDPRESS BLOG POST\nSlug: fbs-vs-serum-free-aav-production-when-to-switch\nSEO Title: FBS vs. Serum-Free for AAV Production \u2014 When to Switch and How | SeamlessBio\nMeta Description: A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.\nFocus Keyword: FBS vs serum-free AAV production switch\nAdditional Keywords: serum-free HEK293T AAV gene therapy GMP, animal component-free AAV medium IND, FBS serum free comparison AAV yield, when to switch serum free viral vector\nCategory: Cell Culture \u00b7 AAV & Viral Vectors\nTags: AAV, HEK293T, FBS, gene therapy, viral vector, cell culture\n--><\/p>\n<style>\n.sb-bp{font-family:-apple-system,BlinkMacSystemFont,\"Segoe UI\",Roboto,sans-serif;max-width:780px;margin:0 auto;padding:0 0 60px;color:#202020;line-height:1.75}\n.sb-bp .lede{font-size:18px;font-weight:500;color:#3a4a50;border-left:4px solid #18b7b2;padding-left:20px;margin:0 0 32px;line-height:1.65}\n.sb-bp h2{font-size:24px;font-weight:800;margin:44px 0 14px;color:#111;padding-bottom:10px;border-bottom:2px solid #e2eceb}\n.sb-bp h3{font-size:18px;font-weight:700;margin:32px 0 10px;color:#18b7b2}\n.sb-bp p{margin:0 0 18px}\n.sb-bp ul,.sb-bp ol{margin:0 0 18px;padding-left:24px}\n.sb-bp li{margin-bottom:8px}\n.sb-bp table{width:100%;border-collapse:collapse;font-size:14px;margin:20px 0 28px;display:block;overflow-x:auto}\n.sb-bp th{background:#18b7b2;color:#fff;text-align:left;padding:10px 14px;font-weight:700;white-space:nowrap}\n.sb-bp td{padding:10px 14px;border-bottom:1px solid #e2eceb;vertical-align:top}\n.sb-bp tr:last-child td{border-bottom:none}\n.sb-bp td:first-child{font-weight:600;color:#111}\n.sb-bp a{color:#18b7b2;text-decoration:none;font-weight:600}\n.sb-bp a:hover{text-decoration:underline}\n.sb-bp strong{color:#111}\n.sb-bp .box{background:#f1faf9;border-left:4px solid #18b7b2;border-radius:0 12px 12px 0;padding:20px 24px;margin:28px 0}\n.sb-bp .cta-box{background:linear-gradient(135deg,#e4f6f5,#f4fbfb);border:1px solid rgba(24,183,178,.2);border-radius:16px;padding:28px;margin-top:44px;text-align:center}\n.sb-bp .cta-box h3{color:#111;margin:0 0 10px}\n.sb-bp .cta-box p{color:#5b6b71;margin:0 0 18px;font-size:15px}\n.sb-bp .cta-btns{display:flex;justify-content:center;gap:12px;flex-wrap:wrap}\n.sb-bp .btn{display:inline-block;background:#18b7b2;color:#fff!important;padding:10px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n.sb-bp .btn-o{display:inline-block;border:2px solid #18b7b2;color:#18b7b2!important;padding:8px 22px;border-radius:8px;font-weight:700;font-size:14px;text-decoration:none!important}\n<\/style>\n<div class=\"sb-bp\">\n<p class=\"lede\">The question is not whether serum-free medium is better than FBS for AAV production \u2014 in terms of titre, a well-optimised serum-free medium matches FBS. The question is when the regulatory, operational, and quality advantages of serum-free outweigh the adaptation cost. This post gives you a practical decision framework by development phase and intended use.<\/p>\n<h2>The honest comparison \u2014 FBS vs. serum-free for AAV<\/h2>\n<table>\n<thead>\n<tr>\n<th>Kriterium<\/th>\n<th>Optimised FBS (Low Endotoxin)<\/th>\n<th>Serum-Free (Chemically Defined)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>AAV titre (optimised)<\/td>\n<td>\u2705 High \u2014 1\u00d710\u00b9\u00b3 \u2013 1\u00d710\u00b9\u2074 vg\/mL achievable<\/td>\n<td>\u2705 Equivalent \u2014 once adapted<\/td>\n<\/tr>\n<tr>\n<td>Chargenkonstanz<\/td>\n<td>\u26a0\ufe0f FBS lot-dependent \u2014 requires lot qualification<\/td>\n<td>\u2705 Zero compositional variability between batches<\/td>\n<\/tr>\n<tr>\n<td>Adaptation cost<\/td>\n<td>\u2705 None \u2014 standard HEK293T culture<\/td>\n<td>\u26a0\ufe0f 3\u20135 passages, potential titre dip during transition<\/td>\n<\/tr>\n<tr>\n<td>TSE\/BSE-Dokumentation<\/td>\n<td>\u26a0\ufe0f Required per lot \u2014 reviewed in IND\/CTA<\/td>\n<td>\u2705 Not required \u2014 no animal components<\/td>\n<\/tr>\n<tr>\n<td>Adventitious agent risk<\/td>\n<td>\u26a0\ufe0f BVDV and other bovine viruses \u2014 requires testing<\/td>\n<td>\u2705 Eliminated \u2014 no animal-derived raw materials<\/td>\n<\/tr>\n<tr>\n<td>Nachgeschaltete Reinigung<\/td>\n<td>\u26a0\ufe0f Bovine albumin co-purifies \u2014 process impurity<\/td>\n<td>\u2705 No bovine protein impurities<\/td>\n<\/tr>\n<tr>\n<td>GMP raw material risk assessment<\/td>\n<td>\u26a0\ufe0f Complex \u2014 FBS is highest-risk category<\/td>\n<td>\u2705 Simplified \u2014 ACF components low-risk<\/td>\n<\/tr>\n<tr>\n<td>Cost per litre of medium<\/td>\n<td>\u2705 Lower \u2014 FBS at 10% is less expensive than full serum-free supplement package at research scale<\/td>\n<td>\u26a0\ufe0f Higher at small scale; comparable at GMP scale<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>Decision framework by development phase<\/h2>\n<h3>Early research (proof-of-concept, in vitro studies)<\/h3>\n<p><strong>Recommendation: FBS Low Endotoxin<\/strong><\/p>\n<p>At this stage, speed and simplicity matter more than regulatory compliance. Optimised FBS gives high, reproducible titres without adaptation time. Use Low Endotoxin grade to avoid TLR4-driven titre suppression. Reserve enough of your validated lot to cover the full research phase.<\/p>\n<h3>Pre-clinical (in vivo mouse\/rat studies, IND-enabling toxicology)<\/h3>\n<p><strong>Recommendation: FBS Low Endotoxin with full documentation package, OR start serum-free transition<\/strong><\/p>\n<p>IND-enabling studies do not formally require serum-free medium, but the FDA and EMA will scrutinise your FBS raw material documentation in the IND\/CTA review. If you plan to use the same manufacturing process for the clinical material, starting the serum-free transition at pre-clinical stage allows you to file the IND with serum-free already established \u2014 avoiding a major process change between pre-clinical and clinical phases.<\/p>\n<h3>IND-enabling \/ first-in-human<\/h3>\n<p><strong>Recommendation: Serum-free chemically defined medium<\/strong><\/p>\n<p>At this stage, serum-free is strongly preferred by regulators. The FDA and EMA both encourage elimination of animal-derived raw materials in ATMP and gene therapy manufacturing. Batch-to-batch consistency of chemically defined medium simplifies the process consistency data required in the IND Chemistry, Manufacturing and Controls (CMC) section. The TSE\/BSE risk assessment burden is eliminated.<\/p>\n<h3>Commercial manufacturing (BLA\/MAA)<\/h3>\n<p><strong>Recommendation: Serum-free chemically defined medium \u2014 mandatory in practice<\/strong><\/p>\n<p>All commercially approved AAV gene therapies (Luxturna, Zolgensma, Hemgenix) are manufactured in serum-free or defined medium. No commercially approved AAV product uses FBS in the final GMP manufacturing process. If you are planning a commercial pathway, starting development in serum-free medium avoids a major process change that would require comparability studies later.<\/p>\n<h2>The transition cost \u2014 what to budget<\/h2>\n<p>The main cost of transitioning from FBS to serum-free is not reagent cost \u2014 it is time and production capacity:<\/p>\n<ul>\n<li><strong>3\u20135 passages adaptation:<\/strong> approximately 2\u20133 weeks for HEK293T<\/li>\n<li><strong>1\u20132 small-scale AAV production runs<\/strong> to confirm titre equivalence before scaling<\/li>\n<li><strong>Doubling time characterisation<\/strong> in the new medium \u2014 required to update your seeding density calculations for target confluency<\/li>\n<li><strong>Stability data<\/strong> for the finished AAV in serum-free conditions \u2014 bovine albumin in FBS-produced AAV provides some stabilisation; serum-free AAV may require formulation buffer optimisation<\/li>\n<\/ul>\n<h2>What to keep from FBS even in serum-free processes<\/h2>\n<p>Some FBS use in AAV production cannot be fully eliminated from day one:<\/p>\n<ul>\n<li><strong>Cell banking:<\/strong> HEK293T master cell banks are typically cryopreserved in FBS-containing medium. Serum-free cell banking is possible but requires optimisation \u2014 many programmes maintain FBS-based MCBs while transitioning production to serum-free<\/li>\n<li><strong>Trypsinisation:<\/strong> standard trypsin is animal-derived. Switch to recombinant trypsin (TrypLE Express, or recombinant porcine trypsin) for ACF compliance<\/li>\n<\/ul>\n<div class=\"cta-box\">\n<h3>FBS and Serum-Free Components for AAV Production<\/h3>\n<p>SeamlessBio supplies both paths: FBS Low Endotoxin for research-grade production, and OsrhHSA + OsrhTF for serum-free transition. Full regulatory documentation available.<\/p>\n<div class=\"cta-btns\">\n<a href=\"https:\/\/seamlessbio.de\/de\/produkte\/fbs-mit-geringem-endotoxingehalt\/\" class=\"btn-o\">FBS, endotoxinarme \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/produkte\/albuminproteine\/\" class=\"btn-o\">rHSA (OsrhHSA) for Serum-Free Medium \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/what-is-recombinant-transferrin\/\" class=\"btn-o\">Recombinant Transferrin OsrhTF \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/ressourcen\/blog\/serum-free-medium-aav-production-complete-recipe\/\" class=\"btn-o\">Serum-Free Medium Component Guide \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/ressourcen\/blog\/fbs-south-american-origin-tse-bse-guide\/\" class=\"btn-o\">FBS South American Origin \u2014 TSE\/BSE Documentation \u2192<\/a><br \/>\n<a href=\"https:\/\/seamlessbio.de\/de\/kontakt\/\" class=\"btn-o\">Request Quote \u2192<\/a>\n<\/div>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>The question is not whether serum-free medium is better than FBS for AAV production \u2014 in terms of titre, a well-optimised serum-free medium matches FBS. The question is when the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-3361","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FBS vs. Serum-Free for AAV Production - When to Switch and How<\/title>\n<meta name=\"description\" content=\"A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/seamlessbio.de\/de\/fbs-vs-serum-free-aav-production-when-to-switch\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FBS vs. Serum-Free for AAV Production - When to Switch and How\" \/>\n<meta property=\"og:description\" content=\"A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/seamlessbio.de\/de\/fbs-vs-serum-free-aav-production-when-to-switch\/\" \/>\n<meta property=\"og:site_name\" content=\"SeamlessBio\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T20:27:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T20:27:31+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\"},\"headline\":\"FBS vs. Serum-Free for AAV Production\",\"datePublished\":\"2026-09-01T20:27:29+00:00\",\"dateModified\":\"2026-09-01T20:27:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/\"},\"wordCount\":666,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/\",\"name\":\"FBS vs. Serum-Free for AAV Production - When to Switch and How\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\"},\"datePublished\":\"2026-09-01T20:27:29+00:00\",\"dateModified\":\"2026-09-01T20:27:31+00:00\",\"description\":\"A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#website\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"name\":\"SeamlessBio\",\"description\":\"Expert for biological materials for pharma, vaccines and research organizations\",\"publisher\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/seamlessbio.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"Place\",\"ProfessionalService\"],\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#organization\",\"name\":\"SeamlessBio\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/\",\"logo\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#local-main-organization-logo\"},\"image\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#local-main-organization-logo\"},\"address\":{\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#local-main-place-address\"},\"telephone\":[\"+49 (851) 37932226\"],\"contactPoint\":{\"@type\":\"ContactPoint\",\"telephone\":\"+49 (851) 37932226\",\"email\":\"info@seamlessbio.de\"},\"openingHoursSpecification\":[{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Monday\",\"Tuesday\",\"Wednesday\",\"Thursday\",\"Friday\"],\"opens\":\"09:00\",\"closes\":\"17:00\"},{\"@type\":\"OpeningHoursSpecification\",\"dayOfWeek\":[\"Saturday\",\"Sunday\"],\"opens\":\"00:00\",\"closes\":\"00:00\"}],\"email\":\"info@seamlessbio.de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/#\\\/schema\\\/person\\\/cd959a5b0b21c02c26d6ffef79f0d529\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/seamlessbio.de\"],\"url\":\"https:\\\/\\\/seamlessbio.de\\\/de\\\/author\\\/admin\\\/\"},{\"@type\":\"PostalAddress\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#local-main-place-address\",\"streetAddress\":\"Dr.-Ernst-Derra-Str. 4\",\"addressLocality\":\"Passau\",\"postalCode\":\"94036\",\"addressRegion\":\"Bavaria\",\"addressCountry\":\"DE\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/seamlessbio.de\\\/fbs-vs-serum-free-aav-production-when-to-switch\\\/#local-main-organization-logo\",\"url\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"contentUrl\":\"https:\\\/\\\/seamlessbio.de\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/134428046-2.png\",\"width\":973,\"height\":288,\"caption\":\"SeamlessBio\"}]}<\/script>\n<meta name=\"geo.placename\" content=\"Passau\" \/>\n<meta name=\"geo.region\" content=\"Deutschland\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FBS vs. Serum-Free for AAV Production - When to Switch and How","description":"A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/seamlessbio.de\/de\/fbs-vs-serum-free-aav-production-when-to-switch\/","og_locale":"de_DE","og_type":"article","og_title":"FBS vs. Serum-Free for AAV Production - When to Switch and How","og_description":"A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.","og_url":"https:\/\/seamlessbio.de\/de\/fbs-vs-serum-free-aav-production-when-to-switch\/","og_site_name":"SeamlessBio","article_published_time":"2026-09-01T20:27:29+00:00","article_modified_time":"2026-09-01T20:27:31+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"admin","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#article","isPartOf":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/"},"author":{"name":"admin","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529"},"headline":"FBS vs. Serum-Free for AAV Production","datePublished":"2026-09-01T20:27:29+00:00","dateModified":"2026-09-01T20:27:31+00:00","mainEntityOfPage":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/"},"wordCount":666,"commentCount":0,"publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/","url":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/","name":"FBS vs. Serum-Free for AAV Production - When to Switch and How","isPartOf":{"@id":"https:\/\/seamlessbio.de\/#website"},"datePublished":"2026-09-01T20:27:29+00:00","dateModified":"2026-09-01T20:27:31+00:00","description":"A practical decision framework for when to switch from FBS to serum-free medium for AAV production in HEK293T \u2014 by development phase, regulatory context and application.","breadcrumb":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/"]}]},{"@type":"WebSite","@id":"https:\/\/seamlessbio.de\/#website","url":"https:\/\/seamlessbio.de\/","name":"SeamlessBio","description":"Experte f\u00fcr biologische Materialien f\u00fcr die Pharmaindustrie, Impfstoffe und Forschungseinrichtungen","publisher":{"@id":"https:\/\/seamlessbio.de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/seamlessbio.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","Place","ProfessionalService"],"@id":"https:\/\/seamlessbio.de\/#organization","name":"SeamlessBio","url":"https:\/\/seamlessbio.de\/","logo":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#local-main-organization-logo"},"image":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#local-main-organization-logo"},"address":{"@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#local-main-place-address"},"telephone":["+49 (851) 37932226"],"contactPoint":{"@type":"ContactPoint","telephone":"+49 (851) 37932226","email":"info@seamlessbio.de"},"openingHoursSpecification":[{"@type":"OpeningHoursSpecification","dayOfWeek":["Monday","Tuesday","Wednesday","Thursday","Friday"],"opens":"09:00","closes":"17:00"},{"@type":"OpeningHoursSpecification","dayOfWeek":["Saturday","Sunday"],"opens":"00:00","closes":"00:00"}],"email":"info@seamlessbio.de"},{"@type":"Person","@id":"https:\/\/seamlessbio.de\/#\/schema\/person\/cd959a5b0b21c02c26d6ffef79f0d529","name":"admin","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c82349c4c3fd3df1cfbb69d5f386d959a89ab4c9dcec1e7889a5140df2c0f1a0?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/seamlessbio.de"],"url":"https:\/\/seamlessbio.de\/de\/author\/admin\/"},{"@type":"PostalAddress","@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#local-main-place-address","streetAddress":"Dr.-Ernst-Derra-Str. 4","addressLocality":"Passau","postalCode":"94036","addressRegion":"Bavaria","addressCountry":"DE"},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/seamlessbio.de\/fbs-vs-serum-free-aav-production-when-to-switch\/#local-main-organization-logo","url":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","contentUrl":"https:\/\/seamlessbio.de\/wp-content\/uploads\/2026\/04\/134428046-2.png","width":973,"height":288,"caption":"SeamlessBio"}]},"geo.placename":"Passau","geo.region":"Deutschland"},"_links":{"self":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/comments?post=3361"}],"version-history":[{"count":1,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3361\/revisions"}],"predecessor-version":[{"id":3362,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/posts\/3361\/revisions\/3362"}],"wp:attachment":[{"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/media?parent=3361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/categories?post=3361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/seamlessbio.de\/de\/wp-json\/wp\/v2\/tags?post=3361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}